Sodium zirconium cyclosilicate
- Generic Name
- Sodium zirconium cyclosilicate
- Brand Names
- Lokelma
- Drug Type
- Small Molecule
- Chemical Formula
- Na2O9Si3Zr
- CAS Number
- 17141-74-1
- Unique Ingredient Identifier
- D652ZWF066
- Background
Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent. It is administered orally and is odorless, tasteless, and stable at room temperature. Approval of the medi...
- Indication
Sodium zirconium cyclosilicate is a potassium binder indicated for the treatment of hyperkalemia in adult patients.
- Associated Conditions
- Hyperkalemia
- Associated Therapies
- -
Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-01-03
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 134
- Registration Number
- NCT04217590
- Locations
- ๐จ๐ณ
Research Site, Yinchuan, China
Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 182
- Registration Number
- NCT03532009
- Locations
- ๐ธ๐ฐ
Research Site, Svidnik, Slovakia
Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months
- First Posted Date
- 2014-06-13
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- ZS Pharma, Inc.
- Target Recruit Count
- 751
- Registration Number
- NCT02163499
Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- ZS Pharma, Inc.
- Target Recruit Count
- 123
- Registration Number
- NCT02107092
Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-03-14
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- ZS Pharma, Inc.
- Target Recruit Count
- 258
- Registration Number
- NCT02088073
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2024. All Rights Reserved by MedPath